Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression
- PMID: 15929396
Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression
Abstract
In this study, 27 HIV-1-positive patients on long-term highly active antiretroviral therapy (HAART) in the Czech Republic were followed for a period of up to 7 years. Variability of the HIV-1 protease (PR) sequence common in the Czech Republic was observed. Under the pressure of inhibitors of protease (PRIs) and reverse transcriptase (RTIs) mutations in PR were detected. Development of resistance to PRIs was followed by a decrease in CD4 count and increase in viral load. The dynamics of viral load closely corresponded to the accumulation of specific primary mutations in PR and RT. Out of 27 patients 18 developed resistance to PRIs and the prolonged therapy led to the accumulation of a higher number of amino acid changes associated with the resistance and, consequently, cross-resistance to several PRIs was observed. These multi-resistant variants of HIV-1 with mutations in PR could not be inhibited sufficiently with PRIs that are currently available in clinical practice. Efficient yet temporary suppression of viral replication was achieved by a lopinavir (LPV) treatment.
Similar articles
-
Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.J Med Virol. 2004 Jul;73(3):350-61. doi: 10.1002/jmv.20098. J Med Virol. 2004. PMID: 15170628
-
Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.J Med Virol. 2003 Aug;70(4):506-12. doi: 10.1002/jmv.10424. J Med Virol. 2003. PMID: 12794711 Clinical Trial.
-
Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.AIDS. 2008 Jul 31;22(12):1417-23. doi: 10.1097/QAD.0b013e3283034953. AIDS. 2008. PMID: 18614864
-
Resistance against reverse transcriptase inhibitors.Clin Infect Dis. 2000 Jun;30 Suppl 2:S185-92. doi: 10.1086/313858. Clin Infect Dis. 2000. PMID: 10860904 Review.
-
Update of the drug resistance mutations in HIV-1: 2004.Top HIV Med. 2004 Oct-Nov;12(4):119-24. Top HIV Med. 2004. PMID: 15516709 Review. No abstract available.
Cited by
-
Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.Antimicrob Agents Chemother. 2012 Aug;56(8):4320-30. doi: 10.1128/AAC.00465-12. Epub 2012 May 29. Antimicrob Agents Chemother. 2012. PMID: 22644035 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials